Trial Profile

A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jan 2026 According to Insmed media release, data from the trial will be presented at the Pulmonary Vascular Research Institute (PVRI) 2026 congress in Dublin from January 28 -February 1, 2026.
22 Sep 2025 According to an Insmed media release, data from this study will be presented in European Respiratory Society (ERS) 2025 Congress's "Abstracts Leading to Evolution in Respiratory Medicine Trials (ALERT)" session- being held September 27 - October 1, 2025, in Amsterdam.
10 Jun 2025 Primary endpoint (Change from Baseline in Pulmonary Vascular Resistance at Week 16) has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com